semaglutide cardiovascular outcomes study 2025 news 2.4 mg delivered a statistically significant 20% risk reduction in major adverse events – REGENHEALTHSOLUTIONS (RHS) Semaglutide SELECT Study: No News

Karl and Spencer discuss the most recent South Park episode where GLP-1 medicines are discussed along with the dysfunctions of our healthcare system among other issues

Q: Why do we use voltage, and not capacity, to determine how charged a battery is

3-month commitment: $99 per month

This is not uncommon and may be related to the body adjusting to a rapid increase in B12 availability, especially in patients who were significantly deficient

Neurexins physically and functionally interact with GABA(A) receptors

The use of Wegovy should be supervised by a qualified clinician who will be responsible for monitoring a patient's response to treatment and in particular any side effects that may arise